Swissmedic approves first bivalent COVID-19 booster vaccine in Switzerland
Bern, 29.8.2022 - Swissmedic has temporarily authorised “Spikevax Bivalent Original/Omicron (mRNA-1273.214)”, the first COVID-19 vaccine containing messenger ribonucleic acid (mRNA) against two coronavirus variants. In trials, a booster dose with this bivalent vaccine demonstrated higher antibody concentrations against the Omicron variants than a booster with Spikevax®, the original COVID-19 vaccine from Moderna, with comparable side effects. The booster vaccine will be used in accordance with the official vaccination recommendations being drawn up by the Federal Commission for Vaccination (FCV) and the Federal Office of Public Health (FOPH).